Clinical Trials for Breast Cancer
1,033 breast cancer trials indexed, 468 currently recruiting. Updated daily from ClinicalTrials.gov.
Understanding Breast Cancer
Breast cancer is a disease where cells in the breast grow uncontrollably and form tumors. These tumors can be benign (non-cancerous) or malignant (cancerous). Malignant tumors have the potential to invade nearby tissues and spread to other parts of the body. Breast cancer usually starts in the ducts that carry milk to the nipple or in the lobules where milk is produced. Doctors diagnose breast cancer through a combination of physical exams, imaging tests like mammograms, ultrasounds, and biopsies where a small sample of tissue is examined under a microscope.
Common symptoms of breast cancer include a lump in the breast or underarm, changes in breast size or shape, skin dimpling, nipple discharge, or pain in the breast. Although breast cancer can occur at any age, it is most commonly diagnosed in women over 50. Women are more affected than men, but men can also develop breast cancer. Risk factors include age, family history, inherited gene mutations such as BRCA1 and BRCA2, exposure to estrogen, obesity, and lifestyle factors like alcohol use and lack of physical activity.
Breast cancer is a major medical and social concern worldwide. It is the most common cancer among women, with over 2.3 million new cases diagnosed globally each year. In the United States, breast cancer accounts for about 30% of all new cancer diagnoses in women. It also has a significant economic impact, with treatment costs and lost productivity reaching billions of dollars annually. Early detection and treatment are crucial because breast cancer is one of the most treatable cancers when found early, but late-stage disease still causes many deaths.
The Breast Cancer Treatment Landscape
The first-line treatment for breast cancer depends on the type, stage, and hormone receptor status of the tumor. Surgery is often the initial step to remove the tumor, followed by radiation therapy to destroy remaining cancer cells. For hormone receptor-positive breast cancers, hormone therapy is a key part of treatment. Chemotherapy may be given before surgery (neoadjuvant) to shrink tumors or after surgery (adjuvant) to reduce recurrence risk. Treatment plans are tailored to each patient and may combine several approaches in a specific order based on guidelines and tumor characteristics.
When breast cancer progresses or returns after initial treatment, second- and third-line options come into play. These include additional chemotherapy drugs such as taxanes and anthracyclines, targeted therapies like HER2 inhibitors (for HER2-positive cancers), and newer hormone therapies for resistant tumors. Drugs like trastuzumab have improved outcomes for HER2-positive breast cancer. Other options may involve immunotherapy or participation in clinical trials testing novel agents. The choice depends on prior treatments, tumor biology, and patient health.
Despite advances, there are still gaps in breast cancer treatment. Some subgroups, such as triple-negative breast cancer, respond poorly to current therapies and have a higher risk of recurrence. Resistance to hormone therapy or chemotherapy can develop over time, limiting effectiveness. Side effects from treatments, including fatigue, nausea, and heart problems, can impact quality of life and adherence. Research is focused on finding new drugs, improving existing treatments, and identifying biomarkers to better predict which patients will benefit from specific therapies.
Why Clinical Trials Matter for Breast Cancer
Clinical trials offer patients the chance to access new treatments that are not yet widely available. They also provide closer monitoring by medical teams and contribute to scientific knowledge that may improve future care. There are currently 1,033 breast cancer clinical trials indexed on ClinicalTrials.gov, with 468 actively recruiting participants. These trials cover a wide range of topics, from new drugs and combinations to prevention and supportive care. Participating in a trial can be a way to receive advanced care while helping others with breast cancer.
It is important to understand the risks associated with clinical trials. Since new treatments are being tested, their effectiveness and safety may not be fully known. Some trials use placebo arms or standard treatments for comparison, which means not all participants receive the experimental treatment. Joining a trial may require additional clinic visits, tests, and follow-up, which can be time-consuming. Side effects from experimental treatments may also occur and need careful management. Patients should discuss these factors with their healthcare providers before enrolling.
Clinical trials for breast cancer are sponsored by a variety of organizations, including academic institutions, pharmaceutical companies, and cooperative research groups. These sponsors design and fund studies to test new ideas and treatments. ClinicalTrials.gov serves as a comprehensive registry, providing public access to information about ongoing and completed trials. This transparency helps patients, caregivers, and doctors find relevant studies and understand the current research landscape in breast cancer.
What to Look for in a Breast Cancer Clinical Trial
Clinical trials are divided into four phases, each with a specific purpose. Phase 1 trials test the safety of a new treatment in a small group of people. Phase 2 trials look at how well the treatment works and continue to monitor safety. Phase 3 trials compare the new treatment to the current standard treatment in larger groups. Phase 4 trials happen after a treatment is approved to gather more information on long-term effects. For breast cancer trials, the current distribution shows 153 trials with no phase specified, 138 in Phase 2, 126 in Phase 1, and 62 in Phase 3. This means most breast cancer trials focus on determining effectiveness and safety in moderate-sized groups.
When considering a breast cancer clinical trial, inclusion criteria are important to understand. These criteria decide who can join based on factors like age, previous treatments, and cancer characteristics. Many trials include adults typically over 18 years old, but some focus on older patients. Prior treatments such as chemotherapy or surgery may be required or excluded. Biomarkers, like hormone receptor status or HER2 status, often determine eligibility. Cancer staging, which describes how far cancer has spread, is also a key factor. Additionally, the length of time since diagnosis or last treatment can affect eligibility.
Exclusion criteria help protect participants by removing those who may face higher risks. Common reasons include having other serious health problems, known as comorbidities, which could interfere with treatment or safety. Some medications may interact badly with trial drugs, so patients taking those may be excluded. Safety thresholds such as blood counts or organ function levels ensure participants are healthy enough for the trial. These criteria aim to reduce complications and ensure the trial results are reliable and safe for participants.
Patients should also think about practical aspects before joining a trial. The length of the trial can vary from a few months to several years. Visit schedules may require frequent trips to the clinic for tests and treatment, which can be challenging. Travel distance and costs should be considered. It is helpful to ask the research team specific questions: How long will the trial last? What types of visits and tests are required? Are there any costs I need to cover? What are the possible side effects of the treatment? These questions help patients understand the commitment and make informed decisions.
Primary Sources and Further Reading
For those interested in learning more about breast cancer clinical trials, reliable sources offer detailed information. These resources provide guidance on trial participation, cancer types, treatments, and ongoing research. Patients and caregivers can use these links to find trustworthy and up-to-date facts.
- National Cancer Institute: Breast Cancer Treatment
- MedlinePlus: Breast Cancer
- ClinicalTrials.gov: Breast Cancer Trials
- Centers for Disease Control and Prevention: Breast Cancer
Latest Research and Emerging Treatments for Breast Cancer (2026)
Breast cancer research continues to explore new drugs and combinations that may improve treatment options for patients. One promising approach involves saruparib (AZD5305) combined with camizestrant, currently being tested against standard therapies like CDK4/6 inhibitors paired with endocrine treatments. Saruparib belongs to a class of drugs called PARP inhibitors, which work by blocking enzymes that help cancer cells repair their DNA, potentially making it harder for the cancer to grow. Camizestrant is an oral selective estrogen receptor degrader, aiming to reduce hormone-driven tumor growth. This trial (NCT06380751) focuses on hormone receptor-positive, HER2-negative advanced breast cancer with specific genetic changes, offering hope for more personalized breast cancer treatment.
Another area of research targets HER2-positive breast cancer, where tucatinib is being tested in combination with ado-trastuzumab emtansine (T-DM1). Tucatinib is a tyrosine kinase inhibitor that blocks signals promoting cancer cell growth, while T-DM1 is an antibody drug conjugate delivering chemotherapy directly to cancer cells. This combination (NCT03975647) is designed to improve disease control in advanced or metastatic HER2-positive breast cancer. For patients, this could mean better management of their cancer with potentially fewer side effects than traditional chemotherapy alone.
For triple-negative breast cancer, which is often more aggressive and harder to treat, trials are studying datopotamab deruxtecan (Dato-DXd) with or without durvalumab. Dato-DXd is an antibody drug conjugate that targets cancer cells and delivers chemotherapy directly to them, while durvalumab is an immunotherapy drug that helps the immune system recognize and attack cancer. These studies (NCT06103864, NCT06112379) are exploring whether combining these treatments can improve survival and reduce the need for chemotherapy. New drugs for breast cancer like these could provide additional options for patients facing limited therapies, especially in difficult-to-treat subtypes.
Frequently asked questions about Breast Cancer trials
How do I find Breast Cancer clinical trials?
The authoritative source for Breast Cancer clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 1,033 breast cancer studies are currently indexed. You can search by entering "breast cancer" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new breast cancer trials and delivers a plain-language briefing every Friday explaining what changed.
What phase are most Breast Cancer trials in?
Across the 1,033 breast cancer trials TrialsAlert indexes, the most common phase is Phase 2. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.
How many Breast Cancer clinical trials are currently recruiting?
As of the latest scan, 468 breast cancer trials have a "Recruiting" status on ClinicalTrials.gov, out of 1,033 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting breast cancer trial matches their tracked condition.
Stay informed about breast cancer research
Get a weekly briefing with the trials that matter most.